Related Experiment Videos
[Early thrombolysis improves the long-term prognosis for patients with a heart infarct]
J Vos1, J G Tijssen, F Vermeer
1Interuniversitair Cardiologisch Instiuut Nederland, Rotterdam.
Insights
Early thrombolytic therapy for myocardial infarction significantly improves long-term survival and patient prognosis compared to conventional treatment. This benefit is most pronounced in specific patient groups, highlighting the value of timely intervention.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- A prior clinical study compared intracoronary streptokinase with conventional therapy for myocardial infarction.
- Long-term patient data were collected to assess the sustained effects of thrombolytic therapy.
Purpose of the Study:
- To evaluate the long-term survival rates and prognosis of patients treated with thrombolytic therapy versus conventional therapy for myocardial infarction.
- To identify patient subgroups that benefit most from early thrombolytic intervention.
Main Methods:
- Retrospective analysis of patient data from 3 to 7 years post-admission.
- Comparison of survival rates, rates of bypass surgery, and percutaneous transluminal coronary angioplasty (PTCA) between treatment groups.
Main Results:
- Three-year survival rates were higher with thrombolysis (87%) compared to conventional therapy (79%).
- Long-term survival differences showed a 6% advantage at 1 year and 10% at 5 years post-treatment.
- Benefits were greatest for anterior infarction, extensive myocardial ischemia, and early treatment post-infarction onset.
- Left ventricular function was the strongest predictor of post-discharge survival.
Conclusions:
- Early thrombolytic therapy for acute myocardial infarction leads to improved long-term survival.
- Timely intervention with thrombolysis offers a significant survival advantage and better prognosis for myocardial infarction patients.
Abstract:
In a previously reported clinical study treatment of myocardial infarction with intracoronary streptokinase (269 patients) was compared with conventional therapy (264 patients). To determine the long-term effects of thrombolytic therapy patient data were collected from 3 to 7 years after admission. Three-year survival rates were 87% after thrombolysis and 79% after conventional therapy. Bypass surgery was done in 19% versus 16%, and PTCA in 9% versus 6% of patients. Patients treated with thrombolysis also had a better prognosis after discharge. The difference in survival between the two treatment groups was 6% after 1 year and 10% after 5 years. Benefit was largest in patients with an anterior infarction, patients with extensive myocardial ischaemia and patients treated shortly after onset of infarction. Left ventricular function appeared to be the best determinant predicting survival after discharge. The findings show that early thrombolysis after acute myocardial infarction also results in improved long-term survival.